SBICAP Securities partners with Appreciate for global market access via GIFT City
SBICAP Securities has partnered with Appreciate Broking IFSC to provide Indian retail investors regulated access to over 8,000 US stocks and global ETFs through GIFT City's infrastructure. The offering features simplified single-KYC onboarding and fractional investing starting at just $1.
SBICAP Securities has announced a partnership with Appreciate Broking IFSC to expand retail investor access to global markets through GIFT City. According to the announcement, the collaboration enables Indian retail investors to gain regulated access to more than 8,000 US stocks and global exchange-traded funds. The platform streamlines the investment process through single-KYC onboarding and offers fractional investing capabilities, allowing investors to start with as little as $1.
This partnership represents a significant development in India's financial infrastructure, particularly through the GIFT City initiative which aims to position India as a global financial hub. The integration of simplified onboarding procedures and low minimum investment thresholds addresses key barriers that have historically limited retail participation in international equity markets. By leveraging GIFT City's regulatory framework and the IFSC designation, the partnership provides a compliant pathway for Indian investors to diversify their portfolios into US and global assets. The fractional investing feature democratizes access to premium stocks that might otherwise require substantial capital outlay. Such initiatives typically benefit market participants seeking portfolio diversification and exposure to developed market equities, while also supporting India's broader objective to establish competitive financial trading and investment platforms on the global stage.
Source: Markets-Economic Times
This article is an editorial summary sourced from third-party news providers and is produced by marketkin.com for informational purposes only. It does not constitute investment advice. Disclaimer